247 related articles for article (PubMed ID: 37720348)
1. Nuclear epidermal growth factor receptor as a therapeutic target.
Atwell B; Chalasani P; Schroeder J
Explor Target Antitumor Ther; 2023; 4(4):616-629. PubMed ID: 37720348
[TBL] [Abstract][Full Text] [Related]
2. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
3. Nuclear EGFR as a molecular target in cancer.
Brand TM; Iida M; Luthar N; Starr MM; Huppert EJ; Wheeler DL
Radiother Oncol; 2013 Sep; 108(3):370-7. PubMed ID: 23830194
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
5. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
7. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation.
Kim JH; Choi HS; Lee DS
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884765
[TBL] [Abstract][Full Text] [Related]
8. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
9. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
10. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.
Yu YL; Chou RH; Liang JH; Chang WJ; Su KJ; Tseng YJ; Huang WC; Wang SC; Hung MC
PLoS One; 2013; 8(4):e61362. PubMed ID: 23593472
[TBL] [Abstract][Full Text] [Related]
11. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai K; Hung MC; Yamaguchi H
Am J Cancer Res; 2016; 6(8):1609-23. PubMed ID: 27648353
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
13. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
14. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
15. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
Yamaoka T; Ohba M; Ohmori T
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
[TBL] [Abstract][Full Text] [Related]
16. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
[TBL] [Abstract][Full Text] [Related]
18. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
19. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
20. The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer.
Kuo HY; Chen YC; Chang HY; Jeng JC; Lin EH; Pan CM; Chang YW; Wang ML; Chou YT; Shih HM; Wu CW
Carcinogenesis; 2013 Aug; 34(8):1708-16. PubMed ID: 23563092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
